Kindstar Globalgene Technology, Inc. disclosed on 2 October 2026 that it bought back 2,500 ordinary shares on the Hong Kong Stock Exchange under its ongoing share-repurchase mandate.

The on-market transaction, executed on 2 October, was priced between HKD 0.91 and HKD 0.92 per share, with a volume-weighted average cost of HKD 0.915. The company paid a total of HKD 2,287.50 for the repurchase. All shares acquired will be held as treasury stock; none were cancelled.

Following the buyback, Kindstar Globalgene’s issued share capital (excluding treasury shares) declined marginally by 0.00024 % to 1.03 billion shares, while treasury shares increased from 9.47 million to 9.48 million. The overall share count, inclusive of treasury shares, remains at 1.04 billion.

The repurchase forms part of the mandate approved by shareholders on 5 June 2026, which authorises the company to buy back up to 103.43 million shares. Cumulative repurchases under this authority now total 2.41 million shares, equivalent to 0.23 % of the share base at the mandate’s inception.

Under Hong Kong Listing Rules, a moratorium is in place prohibiting Kindstar Globalgene from issuing new shares or disposing of treasury shares until 1 November 2026. The disclosure was signed by Executive Director, Chief Financial Officer and Company Secretary, Mr Chai Haijie.